
U.S.
leadership in the technology of biology presents our nation with
tremendous opportunity to build the world’s preeminent bioeconomy by
delivering novel products and processes to society more sustainably and
efficiently.
Many nations
around the world, however, are acting fast to build their bioeconomies
and surpass U.S. scientific and technological dominance to reap the
national security and economic benefits of leadership. We can’t afford
to let this happen.
Advances
in biological sciences hold tremendous promise for realizing solutions
to today’s challenges, from protecting the population from biological
threats and securing access to affordable, sustainable energy to
realizing the promise of precision therapies, agriculture and materials
and maintaining the health of people and the planet.
Biomanufacturing
can transform existing industries and create new ones that are more
profitable, sustainable and efficient than the status quo. Similarly,
smart and modular manufacturing offer significant benefits in terms of
customization, precision and control of therapies, healthcare
instruments and food products.
The United States has pioneered much of the advancements in biosciences. Foundational work in biology, from the Human Genome Project to early advances in synthetic biology, benefitted from significant U.S. federal investments.
These investments directly led to current assets like the Department of Energy’s Environmental Molecular Sciences Laboratory and its Joint Genome Institute
that have extended the progress in biological sciences beyond human
health to advance research in plants, microorganisms and ecosystems.
These
are innovation engines for the nation’s leading scientific research
experts, not just with bioscience technology, product and material
design but also with advanced manufacturing and data management. Public
private partnerships in smart manufacturing and digital manufacturing
are offering enabling technologies that can ignite scientific
discoveries and technological advancements for the future.
Groundbreaking
innovations in biology are already happening in American companies,
universities and national labs. For example, the Joint BioEnergy Institute,
a government-funded partnership among national laboratories and
universities, is leading the way in the development of advanced biofuels
and bioproducts from U.S. biomass — a market potentially worth over
$700 billion for the United States. Jets are already flying with cleaner
and more efficient fuels based on discoveries at the institute.
But
other countries are investing much more aggressively and more
strategically in supporting the growth of their bioeconomies. Dozens of
countries around the world, from China and the United Kingdom to
Thailand and the Netherlands, have published well-defined bioeconomy
roadmaps that identify opportunities, potential bottlenecks and
roadblocks, and strategic areas of investments. The United States has
yet to identify a similar set of strategic investment priorities.
Without one, we are at risk of losing our current leadership position.
To
take full advantage of the potential in biosciences for the United
States, and to capitalize on the advancements that have been realized,
there must be a seismic shift in the way policymakers approach funding
and regulating biosciences and biomanufacturing. Likewise, academia and
industry must demonstrate to the American public the current and future
value of advanced biosciences to U.S. prosperity.
We
cannot hope to make advances without a strategic, aggressive, focused
and coordinated effort to reduce silos and identify synergies among
federal agencies, industry, universities and our national laboratories.
Cross-sector collaboration to advance this key sector of the U.S.
economy is critical.
Organizations like the Council on Competitiveness are
bringing together leaders from these groups to pave the path forward
for competitiveness in bioscience and the manufacturing potential that
ensues. But more must be done at the federal level. The council recently published a report that calls on policymakers in the Trump administration and Congress to take action in the following ways.
First,
develop an annual strategic roadmap for the advancement of bioscience
and biotechnologies to meet energy, environmental, agricultural,
national security and economic goals. Second,
coordinate investments across agencies, broaden disbursement to
cross-disciplinary fields and focus federal investment in the
development of research platforms that more quickly deliver solutions to
society. Third, enable bioscience research platforms to deliver novel
and cost-prohibitive capabilities to industry. Finally, facilitate the
nexus of biology, engineering and manufacturing technology and training.
While
there is hope, significant progress must be made. With continued
cross-sector partnerships, a coordinated effort, and a renewed faith in
the promise of science for a better future, bioscience can transform our
economy and reposition America as a global leader in technology and
innovation.
Comments
Post a Comment